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Abstract 5 
Objective: To determine the risk factors for having diabetic retinopathy (DR) in children and young people 6 
(CYP) with type 1 diabetes (T1DM) at first screening. 7 
Methods: Records from the Diabetes Eye Screening Wales (DESW) service for people in Wales, UK, with 8 
T1DM diagnosed under age 18 years were combined with other electronic health record (EHR) data in the 9 
Secure Anonymised Information Linkage (SAIL) Databank. Data close to the screening date were collected, 10 
and risk factors derived from multivariate, multinomial logistic regression modelling. 11 
Results:  Data from 4,172 persons, with median (Lower Quartile, Upper Quartile) age 16.3 (13.0, 22.3) 12 
years and duration of diabetes 6.6 (2.3, 12.3) years were analysed. 62.6% (n = 2,613) had no DR, 26.7% (n 13 
= 1,112) background DR and 10.7% (n = 447) had referable DR (RDR). No RDR was observed under 19 14 
years of age. Factors associated with an increased risk of DR were diabetes duration, elevated HbA1c and 15 
diastolic blood pressure. People diagnosed with T1DM before age 12 years had an odds ratio of 1.23 for 16 
developing DR for each year they had diabetes, compared with an odds ratio of 1.34 for those diagnosed at 17 
age 12 years or older.  18 
Conclusions: This study found that 37.4% of the study cohort had DR at first screening, the risk being 19 
greater the longer the duration of diabetes or higher the HbA1c and diastolic blood pressure. In addition, 20 
people diagnosed at 12 years of age or over were more likely to have DR with each additional year with 21 
diabetes.  22 
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Introduction 28 
Visual impairment and blindness, as a consequence of diabetic retinopathy (DR), are amongst the most 29 
feared complications of diabetes. The incidence and prevalence of sight-threatening DR (STDR) has 30 
however been slowly decreasing over the last several decades despite the increase in the prevalence of 31 
diabetes (ref.1-7). It has been recently reported in England and Wales that DR is no longer the leading cause 32 
of blindness in the working age population (ref.8). Also in a retrospective analysis of newly recorded 33 
certifications of visual impairment in Wales during 2007-2015 sight loss was reduced by 50% (ref.9). These 34 
observations may reflect the cumulative impact of better management of diabetes, the introduction of 35 
screening programs, better management of risk factors and earlier and more effective ophthalmologic 36 
interventions. 37 
Good glycaemic and blood pressure management are pivotal in both primary prevention and the prevention 38 
of progression of DR. The introduction of intensive insulin therapy to optimise glycaemic management in 39 
children has been observed to have a beneficial effect on DR in multiple studies (ref.10-12). In children aged 40 
13–17 years with type 1 diabetes (T1DM) the risk of developing DR was reduced by 53% (ref.10) while in 41 
children and young people (CYP) aged 12 to 20 years DR was also reduced by 12% to 52% (ref.11). The 42 
benefit of such intensive management in the adolescent years remains evident many years later (legacy 43 
effect) even when HbA1c values deteriorate, becoming similar to those undergoing conventional insulin 44 
therapy (ref.12). Currently, the treatment for STDR, which encompasses severe non-proliferative DR (pre-45 
proliferative DR [PPDR] and proliferative DR (PDR), is primarily by laser photocoagulation and/or 46 
intravitreal injections of inhibitors of vascular endothelial growth factors (anti-VEGF). The relatively recent 47 
addition of anti-VEGF treatment has improved visual outcomes in those with PDR and/or clinically 48 
significant macular oedema (CSMO) (ref.13). Vitrectomy may also be required when these measures are 49 
considered inadequate. It is well accepted that DR remains asymptomatic until it reaches an advanced stage 50 
(STDR) and that the benefit from treatment is best achieved early. This is the basis for the introduction of 51 
screening for DR, which has been shown to be of clinical benefit but also cost-effective (ref.14). The 52 
detection of any DR should help to emphasise the need for improving glycaemic and blood pressure 53 
management, to prevent progression to STDR. 54 
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Previous studies have shown that approximately 0.3% of the Welsh population and 0.2% of CYP under 16 55 
years have T1DM (ref.15, 16).   The prevalence of DR in children and young people (CYP) with diabetes is 56 
low and extremely rare prior to puberty (ref.17, 18). The prevalence of DR has been found in CYP with 57 
diabetes to range between 10.5% and 57.6% depending on the age, duration of diabetes, methods of detecting 58 
DR and the care setting (ref.18-30). The youngest ages at which DR and STDR have been recorded is 5 and 59 
15 years respectively, with the shortest duration of diabetes being 5 years and only five cases of STDR have 60 
been observed in children below the age of 18 years (ref.29, 31). However, these studies involved relatively 61 
small numbers and therefore there is a need to more clearly understand the epidemiology of DR and related 62 
risk factors in a population with T1DM diagnosed below the age of 18 years. 63 
Systematic screening programmes for DR were introduced in the UK in 2003 with the recommendation to 64 
begin screening from the age of 12 years onwards (ref.32). However, the International Society for Paediatric 65 
and Adolescent Diabetes (ISPAD) recommends annual screening to begin earlier from the age of 10 years 66 
or at the onset of puberty, if this is earlier (ref.33). In Wales there exists a single national community based 67 
DR screening programme for all persons with diabetes aged 12 years and over using a standardised quality 68 
assured methodology for image capture and grading of diabetic retinopathy, the guidelines for which 69 
originated from the Airlie House classification and its modified version used in the Early Treatment Diabetic 70 
Retinopathy Study (ref.34, 35) which was simplified for the purpose of populations studies in the UK 71 
(ref.36). Grading involves a primary grader whose findings are checked by a secondary grader with 72 
differences resolved by a more senior tertiary grader to arrive at the final grading. Patients are referred to 73 
the hospital eye service if they have severe pre-proliferative DR, PDR and/or maculopathy for further 74 
assessment and treatment as required. This provided us with a unique opportunity to investigate the risk 75 
factors relating to DR in the population of children and young persons with T1DM diagnosed before the age 76 
of 18 years in Wales, at the time of their first screening event (ref.37).  77 
Methods 78 
The study database was derived from both primary care (Welsh Longitudinal General Practice dataset, 79 
WLGP) and the Diabetic Eye Screening Wales (DESW) dataset and held in the Secure Anonymised 80 
Information Linkage (SAIL) Databank (Swansea University). SAIL is a repository of routinely collected 81 
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electronic health record (EHR) data for people living in or receiving medical services in Wales (ref.38, 39). 82 
This study was reviewed by the independent Information Governance Review Panel (IGRP) of the SAIL 83 
Databank and approved under the ID: 0493. Ethical approval was not required since only anonymised data 84 
was used. 85 
 86 
Data preparation 87 
The study cohort consisted of people in Wales diagnosed with T1DM under the age of 18 years. The method 88 
used to identify persons with T1DM necessitated a recorded diagnosis of T1DM plus a prescription for 89 
insulin close to their earliest diagnosis date, or a hospital inpatient episode because of diabetic ketoacidosis, 90 
or a prescription for a medical device used in the management of T1DM (blood glucose and ketone 91 
monitoring equipment, for example, monitors and testing strips) on at least 5 occasions in the 12-months 92 
following diagnosis. In addition, the Brecon cohort, which is a national register of persons with T1DM 93 
diagnosed while living in Wales below the age of 15 years (ref.40) was also used to ensure the cohort was 94 
as complete as possible. 95 
DESW aims to conduct DR screening annually in all persons with diabetes registered with a GP located in 96 
Wales that meet the eligibility criteria (most notably, persons must be 12 years or older). When a person 97 
attends screening, after testing visual acuity, two 45
◦
 retinal fundus photographs (one centred on the fovea, 98 
and one nasal view) are captured for each eye following mydriasis. Trained graders then assess the images 99 
for the presence of diabetic retinopathy, with images graded according to a standardised grading protocol 100 
(ref.37). The initial dataset consisted of the findings from the initial eye screening event which resulted in a 101 
successful assessment for at least one eye. In addition to the DR grading the current age, age at diagnosis of 102 
diabetes, duration of diabetes, gender and whether the person was referred to a hospital eye department were 103 
recorded.  The following data from primary care GP or reference sources obtained within 6 months of the 104 
date of initial DR screening were also included in the dataset: HbA1c, systolic and diastolic blood pressure, 105 
serum cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, creatinine 106 
and Body Mass Index (BMI). Since this data was derived from the WLGP data, its availability depended on 107 
whether the test was performed by one of the 76% of general practices contributing data to the SAIL 108 
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Databank (ref.41).  A variable indicating whether persons were diagnosed with T1DM before the age of 12 109 
years was also added to the data to enable modelling of interactions with duration of diabetes. 110 
The DESW service commenced in 2003 attaining national coverage in 2007 with all data from both periods 111 
included in this study. The extract of the DESW data in the SAIL Databank used in this study ended at the 112 
end of January 2018. 113 
 114 
Statistical Methods 115 
Median and quartiles are reported as measured values are typically not normally distributed. A univariate analysis 116 
was conducted to investigate differences between the two groups for each individual variable. For continuous 117 
variables the Mann-Whitney U test was employed while categorical variables were investigated using Pearson’s 118 
χ2 test. Secondly, multivariate models were constructed to compare a reference group consisting of people with 119 
no DR with two comparison groups: (i) people with evidence of any DR which was evaluated using binomial 120 
logistic regression and (ii) people with background diabetic retinopathy (BDR) or referable diabetic retinopathy 121 
(RDR, PPDR or worse) separately, which was evaluated using multinomial logistic regression.  122 
Variables from the univariate analysis that were different between groups were used in the initial multivariate 123 
models and backwards stepwise logistic regression was performed until only those variables that differed 124 
significantly remained in the model. People diagnosed with T1DM before the age of 12 years are usually 125 
managed less intensively than those diagnosed after 12 years of age. Therefore, the model included a term that 126 
allowed for the interaction between the duration of diabetes and whether the person was diagnosed with T1DM 127 
under age 12 years or not. The logical variables indicating whether the person was diagnosed before the age of 128 
12 years were retained regardless of whether they differed between groups, in order to evaluate their interaction 129 
with the duration of diabetes. In each of the logistic regression models, Nagelkere’s Pseudo R2 (denoted R2N) 130 
and the in-sample prediction accuracy, A, were used to evaluate the model’s goodness of fit. 131 
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Results 132 
In Wales, during 2003 to 20018, 4495 people were diagnosed with T1DM under the age of 18 years and 133 
invited for DR screening from the age of 12 onwards. 305 (6.7%) did not attend screening and of the 134 
remaining 4190 people only 18 (0.4%) had ungradable images at their first screening event. The median age 135 
of the study cohort at the time of T1DM diagnosis was 10.6 years and at initial DR screening was 16.3 years 136 
with a median duration of diabetes of 6.6 years. The median HbA1c was 72.6 mmol/mol (8.8%) and blood 137 
pressure was 120/70 mmHg. (Table 1).  138 
 139 
Of the 4,172 people with gradable images at their first screening event 62.6% (2,613) did not have any 140 
evidence of DR, 26.7% (1,112) had BDR and 10.7% (447) had RDR with 4.1% (173) having proliferative 141 
DR in one or both eyes (Figure 1). Those who presented with any DR at their first screening event had higher 142 
HbA1c, blood pressure, LDL, cholesterol, creatinine and a longer duration of diabetes and these differences 143 
were even greater in those who presented with a referable level of DR (Supplementary table 1).  144 
People who had had diabetes for a longer time were more likely to have DR at first screening, with the 145 
proportion of the population with DR increasing with increasing duration of diabetes almost linearly up to 146 
approximately 17 years duration (Figure 2a). After 5, 10, 15 and 20 years of diabetes duration 11.0%, 38.6%, 147 
68.4% and 83.9% respectively had evidence of BDR. RDR was only observed in those people having had 148 
diabetes for at least 8 years, thereafter the proportion of people with RDR increased linearly (Figure 2a). We 149 
found, after 10, 15 and 20 years duration 4.6%, 27.9% and 53.6% of people had RDR respectively. None of 150 
the CYP had evidence of RDR before the age of 18 years (Figure 2b). We observed that 11.4% of 12 year 151 
olds at first screening had evidence of early DR, increasing to 31.9% for 18 year olds (Figure 2b). A smaller 152 
proportion of people aged under 12 years at diagnosis of T1DM had DR at first screening than people 153 
diagnosed at age 12 years or older when controlling for duration of diabetes (Figure 2c). Those people 154 
diagnosed with T1DM at or over the age of 12 years acquired an additional risk of developing DR for each 155 
year they had T1DM than people diagnosed under the age of 12 years (Table 2). This difference in the 156 
proportion of people with DR persisted until approximately 20 years duration of diabetes, when the 157 
proportion of people with DR in both groups became comparable (Figure 2c).  158 
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In a multivariate binomial logistic regression analysis, presenting at first screening with an elevated HbA1c 159 
(odds ratio [OR] 1.09) and duration of diabetes (OR 1.23 for people diagnosed under age 12 and 1.34 for 160 
people diagnosed at age 12 or older) carried an increased risk of having DR (Table 2a). In the multivariate, 161 
multinomial model increased HbA1c, diastolic blood pressure and duration of diabetes were observed to 162 
increase the risk of BDR and RDR, with duration of diabetes having the greatest effect (OR 1.22 for BDR 163 
and 1.29 for RDR in people diagnosed under 12 years, and 1.32 and 1.40 for BDR and RDR respectively in 164 
people diagnosed at 12 years or over, Table 2b). The accuracy of the bivariate model was slightly better than 165 
the multivariate model which is to be expected as classifying people into three groups is a more difficult 166 
problem than classifying them into two groups. The Nagelkerke R2N indicates the multivariate model was a 167 
slightly better fit than the bivariate model, but both models fit the data well, having R2N > 0.75. 168 
Discussion 169 
This study involved a large cohort (4172) of children and young people diagnosed with T1DM under the 170 
age of 18 years and investigated the proportion with DR and associated risk factors at their first DR screening 171 
event. In this cohort the presence of any DR was seen in 37.4% and 10.7% had RDR although no one was 172 
found with RDR under the age of 18 years. The fraction of people with BDR at first screening increased 173 
almost linearly with age, with approximately 31.8% having BDR at first screening at age 18. Although none 174 
of the cohort had RDR at their first screening before the age of 19 years there was a linear increase thereafter 175 
increasing to 30.1% at the age of 25 years at first screening. Increased diabetes duration, elevated HbA1c, 176 
and diastolic blood pressure conferred a higher risk of having any DR, BDR or RDR at first screening. 177 
To our surprise our retinal graders recorded the presence of BDR in approximately 10% of our cohort within 178 
the first 2 years after diagnosis at variance with previous studies (ref.35, 42-44). This is difficult to explain 179 
but may in part reflect the high quality of retinal images acquired and the rigorous grading procedure at 180 
DESW and/or a prolonged asymptomatic period prior to the diagnosis of diabetes.  Another contributing 181 
factor may be that many of the diagnoses of DR at this stage is acknowledged to rely on a small number of 182 
microaneurysms, or even a solitary one. Similarly, the DCCT study observed that 9.9% of people with type 183 
1 diabetes had evidence of diabetic retinopathy within the first 2 years since diagnosis, based on 7-field 184 
stereoscopic colour retinal photographs, increasing to 15% with the addition of fluorescein angiography 185 
(ref.45). Consistent with many other studies (ref.46-48), we demonstrated in our study that the longer the 186 
duration of diabetes the greater the risk of developing DR. The proportion with BDR at 5 and 10 years was 187 
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approximately 11.0% and 38.6% respectively, and whereas there was no RDR seen up to 8 years after 188 
diagnosis, at 10 and 20 years duration approximately 4.6% and 53.6% had developed RDR. 189 
We also observed that a greater proportion of those diagnosed with T1DM after the age of 12 years had DR 190 
when compared to those diagnosed prior to 12 years for the same diabetes duration. The median time to DR 191 
in those diagnosed after the age of 12 years was 10 years in comparison to a median time of 12 years in 192 
those diagnosed before the age of 12 years. The adverse impact of puberty on the risk of progression of DR 193 
has been observed in many other populations (ref.42, 49, 50) although not in others (ref.51). 194 
Our study also found that a higher HbA1c was a risk factor for DR at first screening which is in agreement 195 
with many previous studies performed in the UK (ref.5, 46), Europe (ref.47, 52) and the US (ref.48, 53). 196 
The finding that increased diastolic blood pressure specifically increases the risk of DR at first screening is 197 
also in agreement with previous work (ref.48). In CYP hypertension is relatively uncommon and the median 198 
blood pressures in groups that had no DR, BDR and RDR at first screening were all in the normal range for 199 
adults, in particular the median diastolic blood pressure was in the ideal range for all groups. We note 200 
defining hypertension in CYP is usually done with reference to percentiles taking age into account rather 201 
than using absolute cut-offs, but often people with blood pressure under 120/80 mmHg are classified as 202 
having normal blood pressure regardless of age. We observed that a modest increase in diastolic blood 203 
pressure causes a relatively large increase in risk of DR at first screening, even when the diastolic blood 204 
pressure is within the normal range. 205 
Other risk factors for DR found in some previous studies were HbA1c variability, total cholesterol, HDL, age 206 
at diabetes diagnosis (ref.5, 52) and male gender (ref.47). However, in our study cohort we found total 207 
cholesterol, LDL, HDL, triglycerides and gender not to be associated with the occurrence of DR. It is 208 
difficult to compare our results with previous longitudinal studies due to differences in study population and 209 
design. 210 
A limitation of this study was that persons having undertaken screening but did not have additional EHR 211 
data which included the putative risk factors of interest within six months of the screening which was 212 
required by the model and therefore were excluded from the cohort and subsequent analysis. Only if the 213 
measurement of HbA1c is available within 6-months of the screening date is the person included in the model.  214 
Adding more variables to the model compounds this difficulty, leading to quite small cohorts due to the 215 
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relatively high levels of missing data. The key factor that influences whether the data is missing or not is 216 
when the measurements were performed, and since these data are gathered at all times through the year the 217 
data can be considered to be missing at random and consequently will not affect the results of statistical 218 
modelling. This limitation would be common to all study designs that incorporate routine data. Furthermore, 219 
this study did not have access to data from the hospital based ophthalmological services to confirm the 220 
diagnoses of RDR. However, a great advantage of our study is that the cohort of persons with type 1 diabetes 221 
is much larger than has been reported in previous work and that the DESW adopts standardised practices 222 
and data collection methods, and has the ability to link to other EHR data via the SAIL Databank, which 223 
also covers all of Wales. 224 
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Summary 235 
What was known? 236 
 Longitudinal studies have investigated risk factors for diabetic retinopathy in various populations. 237 
 Screening services have improved outcomes and reduced incidence of blindness in people with diabetes. 238 
11 
 People with type 1 diabetes tend to experience poorer outcomes than those with type 2 diabetes because 239 
they often have more difficulty with glycaemic management.  240 
What this paper adds 241 
 In our cohort of people with type 1 diabetes 37.4% had diabetic retinopathy and 10.7% had referable 242 
diabetic retinopathy at first screening.  243 
 We found that diabetes duration, elevated HbA1c, and diastolic blood pressure increase the risk of having 244 
any grade of retinopathy at first screening. 245 
 People diagnosed with type 1 diabetes at or over the age of 12 years acquired a slightly larger additional 246 
risk of DR for each year of diabetes than people diagnosed under the age of 12 years. 247 
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 384 
Figure 1: Proportion of the population with no DR (62.6%), BDR (26.7%) or RDR (10.7%) at 385 
first screening and the proportion of people that have PPDR (2.9%), PDR (2.9%), maculopathy 386 
(2.1%),  PPDR with maculopathy (1.6%) and PDR with maculopathy (1.2%) at first screening. 387 
 388 
Figure 2: Fraction of persons diagnosed with BDR or RDR at first screening as a function of 389 
(a) diabetes duration, (b) age at screening and the fraction of people diagnosed aged less than 390 
12 and aged 12 or older with any DR as a function of diabetes duration (c). 391 
16 
 392 
Table 1: Demographic and laboratory test information on the cohort of people with T1DM at 393 
the time of first DR screening event. 394 
 395 
Table 2: Results from the (a) multivariate binomial logistic regression model (b) multivariate 396 
multinomial logistic regression model. 397 
 398 
17 
Age range 0-6  6-12  12-18  Whole cohort  
Description Count Median (LQ, UQ) Count Median (LQ, UQ) Count Median (LQ, UQ) Count  Median (LQ, UQ) 
Total n 851 (100%)  1747 (100%)  1592 (100%)  4190 (100%)  
Female gender 425 (50%)  914 (52%)  631 (40%)  1971 (47.0%)  
Age at diagnosis (years) 851 (100%) 3.47 (2.2, 4.8) 1747 (100%) 9.5 (8.0, 10.8) 1592 (100%) 14.2 (13.0, 15.9) 4190 (100%) 10.6 (7.0, 13.4) 
Age at screening (years) 851 (100%) 14.2 (12.3, 21.4) 1747 (100%) 14.1 (12.4, 20.6) 1592 (100%) 17.9 (15.2, 24.0) 4190 (100%) 16.3 (13.0, 22.3) 
Diabetes duration (years) 851 (100%) 11.3 (8.9, 17.9) 1747 (100%) 5.6 (3.1, 11.4) 1586 (100%) 2.7 (0.8, 9.8) 4186 (99.9%) 6.6 (2.3, 12.3) 
HbA1c (mmol / mol) 390 (46%) 74.0 (65.0, 86.8) 822 (47%) 73.7 (63.9, 87.7) 743 (47%) 70.4 (56.2, 84.6) 1957 (46.7%) 72.6 (61.7, 86.0) 
HbA1c (%) 390 (46%) 8.9 (8.1, 10.1) 822 (47%) 8.9 (8.0, 10.2) 743 (47%) 8.6 (7.3, 9.9) 1957 (46.7%) 8.8 (7.8, 10.0) 
Systolic pressure (mmHg) 383 (45%) 120.0 (110.0, 130.0) 814 (47%) 119.0 (110.0, 128.0) 931 (59%) 120.0 (110.0, 130.0) 2129 (50.8%) 120.0 (110.0, 130.0) 
Diastolic pressure (mmHg) 383 (45%) 70.0 (62.0, 78.0) 814 (47%) 70.0 (63.0, 78.0) 931 (59%) 70.0 (65.0, 80.0) 2129 (50.8%) 70.0 (61.0, 79.0) 
Cholesterol (mmol/l) 245 (29%) 4.5 (3.9, 5.1) 507 (29%) 4.4 (3.8, 5.1) 639 (40%) 4.3 (3.7, 5.0) 1392 (33.2%) 4.4 (3.8, 5.1) 
LDL (mmol/l) 144 (17%) 2.5 (2.0, 3.0) 302 (17%) 2.3 (1.8, 2.9) 406 (26%) 2.3 (1.8, 2.9) 853 (20.4%) 2.3 (1.8, 2.9) 
HDL (mmol/l) 162 (19%) 1.5 (1.3, 1.7) 334 (19%) 1.4 (1.2, 1.7) 438 (28%) 1.3 (1.1, 1.6) 935 (22.3%) 1.4 (1.2, 1.7) 
Creatinine (µmol/l) 203 (24%) 76.0 (64.5, 89.0) 469 (27%) 73.0 (63.0, 85.0) 656 (41%) 74.0 (63.0, 86.0) 1330 (31.7%) 74 (63, 86) 
BMI (kg/m2) 294 (35%) 23.8 (21.12, 27.2) 611 (35%) 23.4 (21.1, 26.7) 784 (49%) 24.0 (21.3, 27.0) 1691 (40.4%) 23.8 (21.1, 26.9) 
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 (a) 400 
Variable 
OR (95% CI), No 
DR vs. Any DR 
Diabetes duration (diagnosed < 12) 1.23 (1.20, 1.26) 
Diabetes duration (diagnosed >= 12) 1.34 (1.30, 1.37) 
HbA1c (per 10mmol/mol) 1.09 (1.04, 1.15) 
RN2 =0.764 401 
A =0.827 402 
(b) 403 
Variable 
OR (95% CI), No 
DR vs. BDR 
OR (95% CI), 
No DR vs. RDR 
Diabetes duration (diagnosed < 12) 1.22 (1.19, 1.24) 1.29 (1.26, 1.33) 
Diabetes duration (diagnosed >= 12) 1.32 (1.29, 1.36) 1.40 (1.36, 1.44) 
HbA1c (per 10mmol/mol) 1.07 (1.02, 1.14) 1.19 (1.10, 1.29) 
Diastolic pressure 1.02 (1.01, 1.04) 1.04 (1.02, 1.06) 
RN2 =0.782 404 
A =0.721 405 
 406 
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